Precision for Value

Game-changing gene therapies present cost problems for health execsCAR-T therapies have high price tags so it’s important to understand your patient population and budget impact.
Four ways health execs can prep for costly CAR-T cell therapiesWith the high efficacy and dire diagnosis, there will be demand for both Kymriah and Yescarta. Here’s how to manage the monetary impact.
What's missing in hep C drugsPayers have unmet needs in the changing hepatitis C (HCV) space, according to a recent survey. The survey, from Precision for Value, highlights what can be done to encourage payers to ease coverage policies for these drugs in the next wave of HCV treatment.
Payers to pharma: Here’s what we’re missing in hep C drugsA Precision for Value survey highlights what can be done in order to encourage payers to ease coverage policies for these drugs in the next wave of HCV treatment.
Five healthcare policies to expect under President TrumpAs Donald Trump was sworn in as the 45th U.S. president, health policy experts share with Managed Healthcare Executive what’s next for healthcare.
Seven ways the blocked Aetna-Humana merger affects the industryThe proposed megamerger has been shot down. Find out what it means for healthcare execs.